Advertisement
UK markets closed
  • FTSE 100

    8,203.93
    -37.33 (-0.45%)
     
  • FTSE 250

    20,786.65
    +176.31 (+0.86%)
     
  • AIM

    774.39
    +4.97 (+0.65%)
     
  • GBP/EUR

    1.1819
    +0.0021 (+0.18%)
     
  • GBP/USD

    1.2813
    +0.0052 (+0.41%)
     
  • Bitcoin GBP

    45,394.49
    +1,134.47 (+2.56%)
     
  • CMC Crypto 200

    1,206.40
    -2.29 (-0.19%)
     
  • S&P 500

    5,567.19
    +30.17 (+0.54%)
     
  • DOW

    39,375.87
    +67.87 (+0.17%)
     
  • CRUDE OIL

    83.44
    -0.44 (-0.52%)
     
  • GOLD FUTURES

    2,399.80
    +30.40 (+1.28%)
     
  • NIKKEI 225

    40,912.37
    -1.28 (-0.00%)
     
  • HANG SENG

    17,799.61
    -228.67 (-1.27%)
     
  • DAX

    18,475.45
    +24.97 (+0.14%)
     
  • CAC 40

    7,675.62
    -20.16 (-0.26%)
     

London-listed Spectris snaps up US-based Sciaps in £205m deal

At the end of May, Spectris had a net cash position of £398m.
At the end of May, Spectris had a net cash position of £398m.

Precision equipment manufacturer Spectris has agreed a deal to acquire Boston-headquartered Sciaps for $260m (£205m).

The London-listed firm said the transaction, which is still subject to regulatory approval, would be funded by cash with an upfront consideration of $200m (£156.9m) paid on closing. The remaining $60m (£47m) will be paid on the delivery of certain agreed financial metrics.

Andrew Heath, Spectris Chief Executive, said: “Value enhancing M&A is central to our compounding growth strategy.  Sciaps is an excellent business and a great addition to Spectris Scientific, bringing complementary technology and strengthening our offering, including our innovative digital solutions.

ADVERTISEMENT

“The acquisition will strengthen Spectris’ position in a number of key end markets benefiting from long-term, secular and sustainability growth trends, as well as accelerating sales of Sciaps and Malvern Panalytical’s offerings through each other’s sales and distribution channels.”

At the end of May, Spectris had a net cash position of £398m. The group said it would remain in a net cash position with further balance sheet capacity following the transaction.

Sciaps is a high-growth, specialist provider of handheld instruments used to identify minerals and elements in major industries such as mining, metal recycling and agriculture.

The firm is forecast to deliver sales of $70m (£55m) and adjusted earnings before interest, taxation, depreciation and amortisation (EBITDA) of $12.1m (£9.5m).

Don Sackett, CEO of Sciaps, said: “We are delighted to be joining the Malvern Panalytical business under the Spectris Scientific umbrella.  We bring to the portfolio handheld and laser-based (LIBS) elemental analysis, portable benchtop XRF, with a strong new product pipeline and plug-in capability to Malvern Panalytical’s innovative digital platform.

“This is an exciting combination and Spectris is the perfect partner to maximise the success of our combined capabilities and technologies for customers.”